Paul Hoelscher Buys Shares of Sagimet Biosciences Inc. $SGMT
Key Points
- Paul Hoelscher bought 39,567 shares of Sagimet Biosciences Inc. ($SGMT).
- $SGMT last traded around $6.47.
Paul Hoelscher, insider at Sagimet Biosciences Inc. ($SGMT), bought 39,567 shares at an average price of $0.00. The trade was disclosed in a Form 4 filing with the Securities and Exchange Commission.
Sagimet Biosciences Inc. ($SGMT) Stock
Sagimet Biosciences Inc. Earnings
Analysts Set New Price Targets
About Sagimet Biosciences Inc.
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer. It also develops TVB-3567, a FASN inhibitor for the treatment of acne indication; and other oncology programs, such as solid tumor and glioblastoma. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
See Also
This instant news alert was generated by automated narrative technology and financial data from EarningsIQ and public regulatory filings. It is for informational purposes only and is not financial advice.